Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) (NCT01626378) (2013)

Government Record · TauRx Therapeutics Ltd (sponsor) · May 2013

TauRx Therapeutics Ltd (sponsor), 2013-05: Registry entry for the phase 3 trial of TRx0237 200 mg/day versus an active 8 mg/day colourant control in 220 patients with behavioural variant frontotemporal dementia; completed February 2016 with no results posted on the registry.

TRx0237 100 mg tablet will be administered twice daily.

record field (interventions)

TauRx Therapeutics Ltd (sponsor), 2013-05: Registry entry for the phase 3 trial of TRx0237 200 mg/day versus an active 8 mg/day colourant control in 220 patients with behavioural variant frontotemporal dementia; completed February 2016 with no results posted on the registry. Record field; confidence MEDIUM. Study type: interventional, randomised, double-blind, placebo-controlled, phase 3. Enrollment 220 actual. Country: multinational (registry lists sites in North America and Europe); see registry locations. Dose 200 mg/day (100 mg twice daily); control 8 mg/day TRx0237 'placebo'. Primary outcomes ACE-R, FAQ and whole-brain MRI volume at 52 weeks. Status COMPLETED 2016-02; no results posted – 'registered, no results'. Sponsor/funder TauRx Therapeutics Ltd. No peer-reviewed publication of this trial's results was located in PubMed or in the company's publication list as of 2026-11-21. Study type: regulatory record.